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Abstract Paroxysmal kinesigenic dyskinesia (PKD) is a rare neurological disorder character-
ized by recurrent attacks of dyskinetic movements without alteration of consciousness that
are often triggered by the initiation of voluntary movements. Whole-exome sequencing has
revealed a cluster of pathogenic variants in PRRT2 (proline-rich transmembrane protein), a
gene with a function in synaptic regulation that remains poorly understood. Here, we report
the discovery of a novel PRRT2 pathogenic variant inherited in an autosomal dominant pat-
tern in a family with PKD and benign familial infantile seizures (BFIS). After targeted Sanger
sequencing did not identify the presence of previously described PRRT2 pathogenic vari-
ants, we carried out whole-exome sequencing in the proband and her affected paternal
grandfather. This led to the discovery of a novel PRRT2 variant, NM_001256442:exon3:c.
C959T/NP_660282.2:p.A320V, altering an evolutionarily conserved alanine at the amino
acid position 320 located in theM2 transmembrane region. Sanger sequencing further con-
firmed the presence of this variant in four affected family members (paternal grandfather,
father, brother, and proband) and its absence in two unaffected ones (paternal grandmoth-
er and mother). This newly found variant further reinforces the importance of PRRT2 in PKD,
BFIS, and possibly other movement disorders. Future functional studies using animal mod-
els and human pluripotent stem cell models will provide new insights into the role of PRRT2
and the significance of this variant in regulating neural development and/or function.
[Supplemental material is available for this article.]
INTRODUCTION
Paroxysmal kinesigenic dyskinesia (PKD; OMIM 128200) is a rare neurological disorder with
around1500cases reported thus far, affectingapproximately1 in150,000.Thedisease is char-
acterized by a series of involuntary and uncontrollablemotor activities whenever the affected
individual attempts to initiate movements after a period of being static (Nobile and Striano
2014; Ebrahimi-Fakhari et al. 2015; Valtorta et al. 2016). Previous studies have linked this dis-
ease to the PRRT2 (proline-rich transmembrane protein) gene (Chen et al. 2011; Lee et al.
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2012), which is reportedly responsible for amultitude of neurological disorders including not
only PKD but also benign familial infantile seizures (BFIS; OMIM 605751), which occurs in in-
fancywith onset between3 and12moof age and is characterizedby brief seizureswithmotor
arrest, cyanosis, hypertonia, and limb jerks. Seizures respond well to antiepileptic drugs and
usually remit around 2 yr of age (Callenbach et al. 2002). Additional conditions include infan-
tile convulsions and choreoathetosis (ICCA; OMIM 602066) and, in severe cases, intellectual
disability (ID) (Nobile and Striano 2014; Ebrahimi-Fakhari et al. 2015; Valtorta et al. 2016).
Consisting of four exons, the PRRT2 gene resides on Chromosome 16p11.2. Loss-of-
function heterozygous PRRT2 variants have been found in ∼85%–90% of familial cases of
PKD, BFIS, and ICCA. The most common variant identified is the frameshift single-nucleo-
tide duplication NM_001256442:c.649dupC (p.R217fsX224), which was found in 62% of
PKD, ICCA, and BFIS families. Moreover, homozygous PRRT2 variants have been linked to
intellectual disability, emphasizing the importance of the gene in brain development and/
or function. In sporadic cases, many fewer (34% of families) were discovered to have
PRRT2 variants, suggesting either the involvement of other genes or the existence of undis-
covered variants on the PRRT2 gene (Nobile and Striano 2014).
Here we report the identification of a novel pathogenic variant in a family with PKD and
BFIS that is inherited in an autosomal dominant pattern. Targeted sequencing did not iden-
tify the presence of previously described PRRT2 variants in the family. Subsequent whole-
exome sequencing (WES) uncovered a novel variant at the amino acid position 320, which
changed alanine to valine. Sanger sequencing further verified the presence of this variant
in all affected family members and its absence in the unaffected ones. A320 is located in
the carboxy-terminal transmembrane domain, and its evolutionary conservation suggests
functional importance.
RESULTS
Clinical Presentation and Family History
The proband (Individual III-1)’s symptoms started at age 9 1/2, with cramps in both arms and
legs. It was noted that sudden movement triggers symptoms, such as standing up after a
long sitting period or a rapid transition from standstill to running or even walking.
Cramping lasted 15–20 sec. There was no weakness or numbness. Frequencies were irreg-
ular. Since onset, the proband has been stable and is not on medication.
Similar symptomswere present in the father of the proband (II-1) (Fig. 1B), who presented
at a similar age. His symptoms gradually disappeared in his 20s. He was never treated. His
younger brother (II-5) also had similar cramping symptoms. Family history was also notable
for seizures, thought to be BFIS. Seizures were present in the proband’s brother (III-2), pater-
nal grandfather (I-1), and a paternal uncle (II-3) all of whomoutgrew seizures by ages 2–3, and
all of whom have had a normal development without muscle cramping. Together, there was
a strong family history of both PKD and BFIS.
Genomic Analysis
Given the prevalence of PRRT2 variants in PKD and BFIS, we first used Sanger sequencing to
search for possible PRRT2 variants in the proband (Fig. 2A,B). The two previously described
pathogenic variants, c.649dupc and c.133-136delCCAG, were not detected (Fig. 2C).
Although several synonymous changes were discovered, no other variants were uncovered
that might account for the disease phenotypes.
We next carried out WES of the proband (III-1) and her affected paternal grandfather (I-1)
(Table 1). This approach identified the following rare heterozygous variant: NM_001256442:
exon3:c.C959T (NP_660282.2:p.A320V), in exon 3 of PRRT2. We further validated this
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variant by Sanger sequencing. All affected family members carried the variant in heterozy-
gous states, whereas unaffected family members did not have the variant (Fig. 3). Thus,
the segregation of the variant with the phenotype in this family was confirmed.
We also revisited the previous Sanger sequencing data of the proband. Manual evalua-
tion of the sequence chromatograms detected a large peak of C and a small peak that rep-
resented T in the nucleotide position 959, but the base-calling program Phred failed tomake
a call for the variant.
The c.C959T (p.A320V) variant is novel and has not been reported in the 1000 Genomes
Project (2577 samples, build 20130502, accessed November 2015), dbSNP build 131,
Figure 1. Pedigree of the affected family indicates a dominant inheritance pattern with distinct clinical phe-
notypes. (A) Pedigree with individuals numbered. (B) Affected individuals with their known clinical phenotypic
manifestations. At the time of this study, III-2 has not reached the age for the manifestation of PKD.
Figure 2. Sanger sequencing of the PRRT2 gene in the proband excludes the presence of common variants.
(A) PRRT2 gene structure with exons/introns demarcated. Locations of the PCR primers are indicated. (B) Gel
electrophoresis images show the PCR products amplified from the probandgenomicDNAwith various pairs of
primers. (C ) Representative traces from Sanger sequencing show the absence of two commonly detected
PRRT2 variants in the proband.
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Exome Variant Server release ESP6500SI-V2 (6503 samples, accessed November 2015), or
Exome Aggregation Consortium (ExAC) database (60,706 samples, accessed November
2015). It has a Combined Annotation Dependent Depletion (CADD) (Kircher et al. 2014)
score of 20.9, which is in the top 1% of all ∼8.7 billion possible single-nucleotide variants
(SNVs) in terms of predicted deleteriousness. PRRT2 variants are known to cause phenotypes
consistent with those observed in this family.
To shed light on the potential functional significance of this variant, we examined
the position A320 relative to the overall topology of the PRRT2 protein. Based on a previous-
ly reported structural model generated with the Rosetta structure prediction software suite
and molecular dynamics simulation, we found that p.A320 was located in the carboxy-termi-
nal transmembrane domain (Fig. 4A), which is the most conserved part of the protein. We
used an evolutionary approach, termed SAVER, to predict disease-causing single amino
acid substitutions (Adebali et al. 2016), by including orthologous, but not paralogous,
Table 1. PRRT2 (NG_032039.1)
Chr: position
GRCh37 (hg19) HGVS
Gene
coverage
Variant
read
depth
Variant
type
Predicted
effect (SIFT/
PolyPhen)
Population
database MAF Genotype ClinVar ID
16: 29825733 NM_001256442:
exon3: c.C959T
NP_660282.2:
p.A320V
100% at 20× 65 Missense Deleterious/
probably
damaging
None reported Heterozygous SCV000606838
HGVS, Human Genome Variation Society; MAF, mean allele frequency in 1000 Genomes, dbSNP build 131, and ExAC databases.
Figure 3. Segregation of a novel pathogenic PRRT2 variant uncovered via whole-exome sequencing with
phenotypic characteristics of PKD and BFIS. Representative traces from Sanger sequencing show the 100%
concordance of the c.959C>T/p.A320V variant with the affected individuals in the family.
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sequences into consideration. The PRRT2 gene was duplicated in a common ancestor of
bony fishes (Supplemental Fig. S1), and all PRRT2 orthologs in vertebrates contain alanine
in position 320 (Fig. 4B,C; Supplemental Fig. S2), except for bony fishes. The bony fish
PRRT2 orthologs contain serine in this position. Consequently, any substitution of A320, oth-
er than serine, in the human PRRT2 is predicted to be damaging. Together, these observa-
tions suggest that the newly discovered A320V variant is disease-causing.
DISCUSSION
Here we report the finding of a novel pathogenic variant p.A320V in the PRRT2 gene that is
linked to a rare familial neurological disorder, with multifaceted phenotypic presentations in-
cluding PKD and BFIS. The alanine 320 is conserved in PRRT2 orthologs from all vertebrates
examined including the primitive lungfish, with the exception of bony fishes, where the
duplication of the PRRT2 gene and the A320S substitution was detected, which is consistent
with the fact that this clade undergoes rapid genomic evolution (Brazeau and Friedman
Figure 4. The location of alanine 320 in the PRRT2 protein and its evolutionary conservation. (A) A structural
model of the PRRT2 protein transmembrane domains (residues 261–340). The protein backbone is shown as a
schematic, with alanine residues colored in red. Dashed lines indicate putativemembrane limits. The structural
model was from Rossi et al. (2016). (B) Maximum likelihood phylogenic tree of the representative PRRT2 ortho-
logs across vertebrates. The tree is drawn to scale, with branch lengths measured in the number of substitu-
tions per site. All positions containing gaps were eliminated; there were a total of 146 positions in the final
data set. (C ) Multiple protein sequence alignment of the PRRT2 sequence region encompassing the A320 res-
idue in representative vertebrate species. Conserved Ala in position 320 is highlighted in yellow, and Ser,
which is conserved in this position in bony fishes, is highlighted in green. Substitutions in position 307 are high-
lighted in blue. An alignment of this region in all detected PPR2 homologs is shown in Supplemental Figure S2.
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2015). It is also of interest to note that the PRRT2 gene is completely missing from birds,
whereas it is present in earlier branches of life. This might highlight some unique features
of the avian brain, which make the PRRT2 gene function dispensable.
A twist in the discovery of this novel pathogenic variant is worth noting. Given the clear
role of PRRT2 in PKD, the Sanger sequencing method was initially used to sequence this
gene in the proband in our academic laboratory. However, the variant was not called through
a standard base-calling method such as Phred. Remarkably, it was through the WES that this
variant was discovered, which was subsequently confirmed by Sanger sequencing. The initial
miss was due to sole reliance on the base-calling program. Going forward, it is important to
use orthogonal techniques when examining a strong candidate gene suspected to be in-
volved in patients under study. Other base-calling programs such as Mutation Surveyor
can be used to better identify heterozygous variants. It is also critical to manually review se-
quence chromatograms that may contain “double” peaks. Our study exemplifies the power
of exome sequencing to identify variants that could be missed by Sanger sequencing.
The PRRT2 gene is located in an important CNV (copy-number variation) region,
16p11.2. Microduplications of 16p11.2 are associated with schizophrenia (McCarthy et al.
2009), whereas its microdeletion is associated with aortic valve development, seizure disor-
der, and mental retardation (Ghebranious et al. 2007). In addition to PKD and BFIS found in
the family of this study, PRRT2 variants are also involved in other conditions such asmigraine,
hemiplegic migraine, episodic ataxia, and intellectual disability (Nobile and Striano 2014;
Ebrahimi-Fakhari et al. 2015). A recent case report of benign infantile seizures followed by
autistic regression in a boy with 16p11.2 deletion further highlights the importance of
PRRT2 in human brain development (Milone et al. 2017). Despite its importance in human
clinical phenotypes, the biological function of PRRT2 remains poorly understood. Recent
studies using cultured primary mouse neurons show that the protein is enriched in presynap-
tic terminals and plays a critical role in maintaining synaptic numbers and baseline docked
synaptic vesicles at rest. PRRT2-deficient neurons show marked impairment in synchronous
release as a result of a significant decrease in release probability and Ca2+ sensitivity (Valente
et al. 2016; Valtorta et al. 2016). PRRT2 knockout mice have been generated, which show
paroxysmal movements resembling human conditions (Michetti et al. 2017). Future studies
utilizing animal models and human pluripotent stem cell–derived neurons shall further ad-
dress how PRRT2may interact with other synaptic proteins such as SNAP-25 and synaptotag-
min 1/2 to regulate neural circuit dynamics and function.
METHODS
Sample Collection, PCR, and Sanger Sequencing
Saliva samples were collected from individual members of the family for genomic DNA ex-
traction using a kit (OGR-500, Cat# PD-LB-00191, DNA Genotek Inc.). PCR primers were de-
signed according to previously published sequences (Chen 2015) and used to amplify
genomic fragments. PCR products were subjected to Sanger sequencing (Quintara
Biosciences, Inc., SimpliSeq DNA Sequencing) (Table 2). In brief, PCR products were mixed
with one of the PCR primers (serving as the sequencing primer), DNA polymerase, standard
deoxynucleotides, and one of the four dideoxynucleotides (ddATP, ddGTP, ddCTP, or
ddTTP).
WES and Variant Analysis
WeperformedWES in the proband and her affected paternal grandfather. The CCDS exonic
regions and flanking intronic regions totaling ∼51 Mb were captured using the Agilent
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SureSelect XT kit and we performed paired-end 100-bp reads with the Illumina HiSeq2500
platform. Each readwas aligned to the 1000Genomes phase 2 (GRCh37) humangenome ref-
erencewith the Burrows–Wheeler Alignment v.0.5.10-tpx (Li andDurbin 2009). Local realign-
ment around indels and base call quality score recalibration were performed with the
Genome Analysis Toolkit (GATK) (McKenna et al. 2010) v.2.3-9-ge5ebf34. Variant filtering
was done via the Variant Quality Score Recalibration (VQSR) method (DePristo et al. 2011).
For SNVs, the annotations of MQRankSum, HaplotypeScore, QD, FS, MQ, and
ReadPosRankSum were used in the adaptive error model (6 max Gaussians allowed; worst
3% used for training the negative model). HapMap3.331 and Omni2.5 were used as training
sites with HapMap3.3 used as the truth set. SNVs were filtered to obtain all variants up to the
99th percentile of truth sites (1% false negative rate). For indels, the annotations of QD, FS,
HaplotypeScore, and ReadPosRankSum were used in the adaptive error model (4 max
Gaussians allowed; worst 12% used for training the negative model; indels that had annota-
tions of >10 SD from themean were excluded from the Gaussian mixturemodel). A set of cu-
rated indels obtained from the GATK resource bundle (Mills_and_1000G_gold_ standard.
indels.b37.vcf) were used as training and truth sites. Indels were filtered to obtain all variants
up to the 95th percentile of truth sites (5% false negative rate). Using the PhenoDB Variant
Analysis Tool of PhenoDB, we prioritized heterozygous, homozygous, and compound het-
erozygous rare functional variants (missense, nonsense, splice site variants, and indels) shared
by the proband and her paternal grandfather. The variants were furthered filtered using
OMIMphenotypes thatmatched thephenotypic features of the probandandpaternal grand-
father entered into PhenoDB (Sobreira et al. 2015). We excluded variants with a minor allele
frequency (MAF) of >0.01 in dbSNP 126, 129, and 131, the Exome Variant Server (release
ESP6500SI-V2), 1000 Genomes Project or among the samples sequenced at CIDR as part
of the BHCMG. Only the reported variant in the PRRT2 gene was uncovered.
Evolutionary Sequence Analysis
Orthologs of the human PRRT2 protein were identified by BLAST searches against the NCBI
RefSeq database, followed by a multiple sequence alignment and construction of the max-
imum likelihood phylogenetic tree using MEGA7 (Kumar et al. 2016). Gene duplication
events were inferred from the tree topology and paralogous sequences were excluded
from further analysis. Conservation of individual amino acid positions was assessed using
a custom consensus script.
ADDITIONAL INFORMATION
Data Deposition and Access
The sequence data for the two individuals whose DNA underwent exome sequencing (III-1
[BH8378_1] and I-1 [BH8378_8]) were submitted to dbGaP with a submission number
phs000711.v5.p2. The PRRT2 variant has been submitted to ClinVar (http://www.ncbi.nlm.
nih.gov/ clinvar/) under accession number SCV000606838.
Table 2. Sequencing results
Patient
Total
reads
Total
mapped
reads
Filtered
variants
Yield
(Gb)
Mean
target
coverage
Mean target
coverage
>20× (%)
>Q30
(%)
Mean
Q
III-1 71947232 66390616 138584 6.62 72.1 93.1 94.3 36
I-1 68909304 62494642 138460 6.23 66.8 91.7 94.3 36
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